This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mabuchi, H. Articles by Croce, C. M. Search for Related Content PubMed PubMed Citation Articles by Mabuchi, H. Articles by Croce, C. M.

Cloning and Characterization of CLLD6, CLLD7, and CLLD8, Novel Candidate Genes for Leukemogenesis at Chromosome 13q14, a Region Commonly Deleted in B-Cell Chronic Lymphocytic Leukemia¹

Kimmel Cancer Center, Thomas Jefferson Medical College, Philadelphia, Pennsylvania 19107 [H. M., H. F., G. C., H. A., M. N., F. B., C. M. C.], and the CLL Research Consortium [C. M. C., L. R., T. J. K.], University of California, San Diego [L. R., T. J. K.], La Jolla, California 92083

Chromosome 13q14 deletions constitute the most common structural aberration in B-cell chronic lymphocytic leukemia (B-CLL). We constructed a high-resolution physical map covering the critical deleted region in B-CLL at 13q14 and flanking sequences. The order and position of both genomic markers and known genes were determined precisely. Three novel genes, CLLD6, CLLD7, and CLLD8, were isolated and characterized. The predicted protein sequence of CLLD6 revealed no homology with known proteins. However, both CLLD7 and CLLD8 predicted proteins contain known functional domains. CLLD7 has both an RCC1 and a BTB domain, and could thus be involved in cell cycle regulation by chromatin remodeling. CLLD8 contains a methyl-CpG binding, a preSET and a SET domain, suggesting that CLLD8 might be associated with methylation-mediated transcriptional repression. Mutation analysis of hematopoietic tumor cell lines and B-CLL tumor samples revealed no point mutations within the coding region of these three novel genes. The functional domains present within CLLD7 and CLLD8 suggest that the proteins may be involved in critical cellular processes such as cell cycle and transcriptional control and could therefore be directly or indirectly involved in leukemogenesis.

This article has been cited by other articles:

				P. Ouillette, H. Erba, L. Kujawski, M. Kaminski, K. Shedden, and S. N. Malek Integrated Genomic Profiling of Chronic Lymphocytic Leukemia Identifies Subtypes of Deletion 13q14 Cancer Res., February 15, 2008; 68(4): 1012 - 1021. [Abstract] [Full Text] [PDF]

				S. Deaglio, T. Vaisitti, R. Billington, L. Bergui, P. Omede', A. A. Genazzani, and F. Malavasi CD38/CD19: a lipid raft-dependent signaling complex in human B cells Blood, June 15, 2007; 109(12): 5390 - 5398. [Abstract] [Full Text] [PDF]

				F. Petrocca, D. Iliopoulos, H. R. Qin, M. S. Nicoloso, S. Yendamuri, S. E. Wojcik, M. Shimizu, G. Di Leva, A. Vecchione, F. Trapasso, et al. Alterations of the Tumor Suppressor Gene ARLTS1 in Ovarian Cancer Cancer Res., November 1, 2006; 66(21): 10287 - 10291. [Abstract] [Full Text] [PDF]

				G. A. Calin, F. Trapasso, M. Shimizu, C. D. Dumitru, S. Yendamuri, A. K. Godwin, M. Ferracin, G. Bernardi, D. Chatterjee, G. Baldassarre, et al. Familial Cancer Associated with a Polymorphism in ARLTS1 N. Engl. J. Med., April 21, 2005; 352(16): 1667 - 1676. [Abstract] [Full Text] [PDF]

				M.-S. Hung and C.-K. J. Shen Eukaryotic Methyl-CpG-Binding Domain Proteins and Chromatin Modification Eukaryot. Cell, October 1, 2003; 2(5): 841 - 846. [Full Text] [PDF]

				J. Shaughnessy Jr Primer on Medical Genomics Part IX: Scientific and Clinical Applications of DNA Microarrays--Multiple Myeloma as a Disease Model Mayo Clin. Proc., September 1, 2003; 78(9): 1098 - 1109. [Abstract] [PDF]

				J. Shaughnessy, J. Jacobson, J. Sawyer, J. McCoy, A. Fassas, F. Zhan, K. Bumm, J. Epstein, E. Anaissie, S. Jagannath, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression Blood, May 15, 2003; 101(10): 3849 - 3856. [Abstract] [Full Text] [PDF]

				G. A. Calin, C. D. Dumitru, M. Shimizu, R. Bichi, S. Zupo, E. Noch, H. Aldler, S. Rattan, M. Keating, K. Rai, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia PNAS, November 26, 2002; 99(24): 15524 - 15529. [Abstract] [Full Text] [PDF]

				U. Novak, E. Oppliger Leibundgut, J. Hager, D. Muhlematter, M. Jotterand, C. Besse, N. Leupin, D. Ratschiller, J. Papp, G. Kearsey, et al. A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL) Blood, August 13, 2002; 100(5): 1787 - 1794. [Abstract] [Full Text] [PDF]

				D. Mertens, S. Wolf, P. Schroeter, C. Schaffner, H. Dohner, S. Stilgenbauer, and P. Lichter Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia Blood, May 13, 2002; 99(11): 4116 - 4121. [Abstract] [Full Text] [PDF]

				U. Klein, Y. Tu, G. A. Stolovitzky, M. Mattioli, G. Cattoretti, H. Husson, A. Freedman, G. Inghirami, L. Cro, L. Baldini, et al. Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells J. Exp. Med., December 3, 2001; 194(11): 1625 - 1638. [Abstract] [Full Text] [PDF]

				Y. Zhang and D. Reinberg Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails Genes & Dev., September 15, 2001; 15(18): 2343 - 2360. [Full Text] [PDF]

				F. Bullrich, H. Fujii, G. Calin, H. Mabuchi, M. Negrini, Y. Pekarsky, L. Rassenti, H. Alder, J. C. Reed, M. J. Keating, et al. Characterization of the 13q14 Tumor Suppressor Locus in CLL: Identification of ALT1, an Alternative Splice Variant of the LEU2 Gene Cancer Res., September 1, 2001; 61(18): 6640 - 6648. [Abstract] [Full Text] [PDF]